VALIDATED EXECUTIVE ENGAGEMENTS
POOL + OUTREACH
13394
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
1607
Interactions with Platform & by Email
PARTICIPANTS
402
Unique # Participated
VALIDATIONS
181
Responses Validated*
* Login to view program details and full enterprise executive list.
DATE
JULY 2020
TABLES
108
PAGES
278
EDITION
16
PRICE
USD $5600
The U.S. Economy is Reinventing Itself to Weather Economic Storms.
Here's An Analytical Window into the Changing Opportunities.
Amid the COVID-19 crisis, the global market for Orphan Drugs estimated at US$165.5 Billion in the year 2020, is projected to reach a revised size of US$371.4 Billion by 2027, growing at aCAGR of 12.2% over the period 2020-2027. Biologics, one of the segments analyzed in the report, is projected to record 11.5% CAGR and reach US$217.3 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Non-Biologics segment is readjusted to a revised 13.4% CAGR for the next 7-year period.
The Orphan Drugs market in the U.S. is estimated at US$48.8 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$65.2 Billion by the year 2027 trailing a CAGR of 11.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 10.9% and 10.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 8.9% CAGR.We bring years of research experience to this 16th edition of our report. The 278-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.
AbbVie Inc.; Actelion Pharmaceuticals Ltd.; Alexion Pharmaceuticals Inc.; Amgen Inc.; AstraZeneca Plc.; Bayer AG; Biogen Inc.; BioMarin Pharmaceutical Inc.; Boehringer Ingelheim GmbH; Bristol-Myers Squibb Company; Celgene Corp.; CEL-SCI Corporation; Concordia International Corp.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd.; Genzyme Corp.,; Johnson & Johnson; Merck & Co. Inc.; Merck Serono SA; Novartis AG; Pfizer Inc.; Recordati S.p.A.; Sanofi SA; Shire Plc.; Vertex Pharmaceuticals
» Drug Type (Biologics, Non-Biologics) » Disease Type (Oncology, Hematology, Neurology, Cardiovascular, Other Disease Types)
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
INSIDER ACCESS PRIVILEGES
Users of our portal have insider access to our data stacks based on project relevance and engagement status. Tiered access is offered to data stacks, managed based on user status - Opt-in, Active Panelist, Inactive Panelist, Active Client or Inactive Client.
KEY DIFFERENTIATORS
We are firmly committed to build upon perspectives from global executive insights. These engagements enrich our projects. Our primary research programs are fully validated and accessible by clients. (Its a common industry-wide* practice that no validated primary research is done! For the most part, remote resident analysts curate and write reports drawing on search engine research and data modeling.
* A review of 262 off-the-shelf market report publishers worldwide.
WHAT SETS US APART
Client companies can access multiple features on our MarketGlassâ„¢ platform.
Clients have full-stack insider access to our ongoing primary research program. We have a very successful incentive driven primary research program that benefits participating executives regardless of their purchase decision. Our platform presents a unique opportunity to collaborate with peers and review competitors’ inputs and response clusters.
Detailed engagement stats are presented for every company and executive contacted. This is made available for our client reviews. (no other publisher offers this!)
A full-stack access to clients of all primary and secondary source content. This can often run into thousands of pages.
Where relevent and possible we present competitive brands.
Peer-to-peer online interactive collaborations. Allows for team curated bespoke analytics.
Customers can update and build bespoke versions of our analytics. Bespoke updates are fulfilled within a two-day turnaround.
Discretely bounce off queries to participant pool of executives. Our embedded AI selectively pings participants geographically and by domain acumen.
We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.
Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.
All updates are offered for one year from date of your purchase without charge. Clients can opt for annual auto renewal and stay current without interruption.
05
| I. INTRODUCTION, METHODOLOGY & REPORT SCOPE |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| A Prelude |
| Recent Market Activity |
| Increasing Adoption of Orphan Drugs by Manufacturers |
| The 1983 Orphan Drugs Act (ODA) Kickstarts the Industry |
| Major Orphan Drugs Legislations Worldwide |
| Orphan Drugs Market on a Rapid Growth Trajectory |
| Select Major Organizations Dealing with Rare Diseases in the US, Canada, and EU |
| Incentives for Orphan Drug Designation Products in the US, EU, and Japan |
| Market Challenges |
| Obstacles for Conducting Orphan Drug Research |
| Competition |
| Orphan Drugs Remain Strong in the Pharmaceutical Pipeline |
| Important Orphan Drugs in Pipeline |
| Global Competitor Market Shares |
| Orphan Drugs Competitor Market Share Scenario Worldwide (in %): 2020 & 2029 |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| AbbVie, Inc. (USA) |
| Actelion Pharmaceuticals Ltd. (Switzerland) |
| Alexion Pharmaceuticals, Inc. (USA) |
| Amgen, Inc. (USA) |
| AstraZeneca Plc. (UK) |
| Bayer AG (Germany) |
| Biogen Inc. (USA) |
| BioMarin Pharmaceutical Inc. (USA) |
| Boehringer Ingelheim GmbH (Germany) |
| Bristol-Myers Squibb Company (USA) |
| Celgene Corp. (USA) |
| CEL-SCI Corporation (USA) |
| Concordia International Corp. (Canada) |
| Eli Lilly and Company (USA) |
| F. Hoffmann-La Roche Ltd. (Switzerland) |
| Johnson & Johnson (USA) |
| Merck & Co., Inc. (USA) |
| Merck Serono International S.A. (Germany) |
| Merck Serono International S.A. (Germany) |
| Novartis AG (Switzerland) |
| Pfizer, Inc. (USA) |
| Recordati S.p.A. (Italy) |
| Orphan Europe (France) |
| Shire Plc. (Ireland) |
| Sanofi SA (France) |
| Genzyme Corp. (USA) |
| Vertex Pharmaceuticals (USA) |
| 3. MARKET TRENDS & DRIVERS |
| Regulatory Incentives - A Push in the Right Direction |
| Growing Unmet Medical Needs - Fulfilling the Gap |
| Rising Incidence of Rare Forms of Cancer - Opportunities Galore |
| Select Orphan Drugs for Cancer |
| Rise in Incidence of Renal Cell Carcinoma |
| Unmet Needs in AML |
| Aging Population Offers Growth Potential |
| Pre-Symptomatic Screening to Expand Market Base |
| Asia’s Rising Awareness and Growing Population to Drive Sales |
| Drug Repurposing Provides Therapies for Rare Diseases |
| The Trend of Old Drugs Re-Surfacing as Orphan Drugs Surges |
| Interest of Major Pharmaceutical Firms Signal a Shift in Commercial Dynamics |
| Mergers and Acquisitions Drive Market Growth |
| Select Mergers & Acquisitions for Orphan Drugs as of the Year 2016 |
| Growing Scrutiny over Skyrocketing Prices |
| Orphan Drugs with High Prices: 2016 |
| Medical Advancements Foster Growth |
| Full Reimbursements Critical for Spurring Uptake of High-Priced Orphan Drugs |
| Regulators to Scrutinize Exorbitant Pricing of Ultra-Orphan Drugs |
| Strong Market Potential for Ultra-Orphan Drugs for Amyloid Light-chain Amyloidosis |
| Increasing Patient Engagement - The PAG Trend |
| Gene Therapy and Bioprocessing Preferred over Chronic Therapies |
| Companies Developing Gene Therapies |
| International Collaboration - The Way Forward |
| CNS Therapeutics to Gain Focus in the Orphan Drugs Market |
| Manufacturers Target Orphan Indications to Curtail Competition in Broader Indications |
| Manufacturers Use Orphan Disease to Target Larger Therapeutic Indications |
| Treating Autism - The Next Big Thing? |
| Sequencing Technology - The New Research Tool for Orphan Drugs |
| Innovations in Biotechnology - A Boon for Orphan Drug Research |
| Aging Gene Linked to Myeloma |
| Antibody with Potential to Treat Multiple Myeloma |
| Potential Treatment for Cystic Fibrosis Patients Infected with Mycobacterium abscessus |
| Genetic Variants to Improve Treatment of Non-small Cell Lung Cancer |
| 4. GLOBAL MARKET PERSPECTIVE |
| Orphan Drugs Global Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025 |
| Orphan Drugs Global Retrospective Market Scenario in US$ Million by Region/Country: 2009-2017 |
| Orphan Drugs Market Share Shift across Key Geographies Worldwide: 2009 VS 2019 VS 2025 |
| Biologics (Drug Type) World Market by Region/Country in US$ Million: 2018 to 2025 |
| Biologics (Drug Type) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017 |
| Biologics (Drug Type) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025 |
| Non-Biologics (Drug Type) Potential Growth Markets Worldwide in US$ Million: 2018 to 2025 |
| Non-Biologics (Drug Type) Historic Market Perspective by Region/Country in US$ Million: 2009 to 2017 |
| Non-Biologics (Drug Type) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025 |
| Oncology (Disease Type) Geographic Market Spread Worldwide in US$ Million: 2018 to 2025 |
| Oncology (Disease Type) Region Wise Breakdown of Global Historic Demand in US$ Million: 2009 to 2017 |
| Oncology (Disease Type) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025 |
| Hematology (Disease Type) World Market Estimates and Forecasts by Region/Country in US$ Million: 2018 to 2025 |
| Hematology (Disease Type) Market Historic Review by Region/Country in US$ Million: 2009 to 2017 |
| Hematology (Disease Type) Market Share Breakdown by Region/Country: 2009 VS 2019 VS 2025 |
| Neurology (Disease Type) World Market by Region/Country in US$ Million: 2018 to 2025 |
| Neurology (Disease Type) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017 |
| Neurology (Disease Type) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025 |
| Cardiovascular (Disease Type) World Market Estimates and Forecasts in US$ Million by Region/Country: 2018 to 2025 |
| Cardiovascular (Disease Type) Market Worldwide Historic Review by Region/Country in US$ Million: 2009 to 2017 |
| Cardiovascular (Disease Type) Market Percentage Share Distribution by Region/Country: 2009 VS 2019 VS 2025 |
| Other Disease Types (Disease Type) Market Opportunity Analysis Worldwide in US$ Million by Region/Country: 2018 to 2025 |
| Other Disease Types (Disease Type) Global Historic Demand in US$ Million by Region/Country: 2009 to 2017 |
| Other Disease Types (Disease Type) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025 |
| III. MARKET ANALYSIS |
| GEOGRAPHIC MARKET ANALYSIS |
| United States |
| Market Facts & Figures |
| US Orphan Drugs Market Share (in %) by Company: 2020 & 2025 |
| United States Orphan Drugs Market Estimates and Projections in US$ Million by Drug Type: 2018 to 2025 |
| Orphan Drugs Market in the United States by Drug Type: A Historic Review in US$ Million for 2009-2017 |
| United States Orphan Drugs Market Share Breakdown by Drug Type: 2009 VS 2019 VS 2025 |
| United States Orphan Drugs Market Estimates and Projections in US$ Million by Disease Type: 2018 to 2025 |
| Orphan Drugs Market in the United States by Disease Type: A Historic Review in US$ Million for 2009-2017 |
| United States Orphan Drugs Market Share Breakdown by Disease Type: 2009 VS 2019 VS 2025 |
| Canada |
| Canadian Orphan Drugs Market Estimates and Forecasts in US$ Million by Drug Type: 2018 to 2025 |
| Canadian Orphan Drugs Historic Market Review by Drug Type in US$ Million: 2009-2017 |
| Orphan Drugs Market in Canada: Percentage Share Breakdown of Sales by Drug Type for 2009, 2019, and 2025 |
| Canadian Orphan Drugs Market Estimates and Forecasts in US$ Million by Disease Type: 2018 to 2025 |
| Canadian Orphan Drugs Historic Market Review by Disease Type in US$ Million: 2009-2017 |
| Orphan Drugs Market in Canada: Percentage Share Breakdown of Sales by Disease Type for 2009, 2019, and 2025 |
| Japan |
| Japanese Market for Orphan Drugs: Annual Sales Estimates and Projections in US$ Million by Drug Type for the Period 2018-2025 |
| Orphan Drugs Market in Japan: Historic Sales Analysis in US$ Million by Drug Type for the Period 2009-2017 |
| Japanese Orphan Drugs Market Share Analysis by Drug Type: 2009 VS 2019 VS 2025 |
| Japanese Market for Orphan Drugs: Annual Sales Estimates and Projections in US$ Million by Disease Type for the Period 2018-2025 |
| Orphan Drugs Market in Japan: Historic Sales Analysis in US$ Million by Disease Type for the Period 2009-2017 |
| Japanese Orphan Drugs Market Share Analysis by Disease Type: 2009 VS 2019 VS 2025 |
| China |
| Chinese Orphan Drugs Market Growth Prospects in US$ Million by Drug Type for the Period 2018-2025 |
| Orphan Drugs Historic Market Analysis in China in US$ Million by Drug Type: 2009-2017 |
| Chinese Orphan Drugs Market by Drug Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 |
| Chinese Orphan Drugs Market Growth Prospects in US$ Million by Disease Type for the Period 2018-2025 |
| Orphan Drugs Historic Market Analysis in China in US$ Million by Disease Type: 2009-2017 |
| Chinese Orphan Drugs Market by Disease Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 |
| Europe |
| Market Facts & Figures |
| European Orphan Drugs Market: Competitor Market Share Scenario (in %) for 2020 & 2025 |
| European Orphan Drugs Market Demand Scenario in US$ Million by Region/Country: 2018-2025 |
| Orphan Drugs Market in Europe: A Historic Market Perspective in US$ Million by Region/Country for the Period 2009-2017 |
| European Orphan Drugs Market Share Shift by Region/Country: 2009 VS 2019 VS 2025 |
| European Orphan Drugs Market Estimates and Forecasts in US$ Million by Drug Type: 2018-2025 |
| Orphan Drugs Market in Europe in US$ Million by Drug Type: A Historic Review for the Period 2009-2017 |
| European Orphan Drugs Market Share Breakdown by Drug Type: 2009 VS 2019 VS 2025 |
| European Orphan Drugs Market Estimates and Forecasts in US$ Million by Disease Type: 2018-2025 |
| Orphan Drugs Market in Europe in US$ Million by Disease Type: A Historic Review for the Period 2009-2017 |
| European Orphan Drugs Market Share Breakdown by Disease Type: 2009 VS 2019 VS 2025 |
| France |
| Orphan Drugs Market in France by Drug Type: Estimates and Projections in US$ Million for the Period 2018-2025 |
| French Orphan Drugs Historic Market Scenario in US$ Million by Drug Type: 2009-2017 |
| French Orphan Drugs Market Share Analysis by Drug Type: 2009 VS 2019 VS 2025 |
| Orphan Drugs Market in France by Disease Type: Estimates and Projections in US$ Million for the Period 2018-2025 |
| French Orphan Drugs Historic Market Scenario in US$ Million by Disease Type: 2009-2017 |
| French Orphan Drugs Market Share Analysis by Disease Type: 2009 VS 2019 VS 2025 |
| Germany |
| Orphan Drugs Market in Germany: Recent Past, Current and Future Analysis in US$ Million by Drug Type for the Period 2018-2025 |
| German Orphan Drugs Historic Market Analysis in US$ Million by Drug Type: 2009-2017 |
| German Orphan Drugs Market Share Breakdown by Drug Type: 2009 VS 2019 VS 2025 |
| Orphan Drugs Market in Germany: Recent Past, Current and Future Analysis in US$ Million by Disease Type for the Period 2018-2025 |
| German Orphan Drugs Historic Market Analysis in US$ Million by Disease Type: 2009-2017 |
| German Orphan Drugs Market Share Breakdown by Disease Type: 2009 VS 2019 VS 2025 |
| Italy |
| Italian Orphan Drugs Market Growth Prospects in US$ Million by Drug Type for the Period 2018-2025 |
| Orphan Drugs Historic Market Analysis in Italy in US$ Million by Drug Type: 2009-2017 |
| Italian Orphan Drugs Market by Drug Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 |
| Italian Orphan Drugs Market Growth Prospects in US$ Million by Disease Type for the Period 2018-2025 |
| Orphan Drugs Historic Market Analysis in Italy in US$ Million by Disease Type: 2009-2017 |
| Italian Orphan Drugs Market by Disease Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 |
| United Kingdom |
| United Kingdom Market for Orphan Drugs: Annual Sales Estimates and Projections in US$ Million by Drug Type for the Period 2018-2025 |
| Orphan Drugs Market in the United Kingdom: Historic Sales Analysis in US$ Million by Drug Type for the Period 2009-2017 |
| United Kingdom Orphan Drugs Market Share Analysis by Drug Type: 2009 VS 2019 VS 2025 |
| United Kingdom Market for Orphan Drugs: Annual Sales Estimates and Projections in US$ Million by Disease Type for the Period 2018-2025 |
| Orphan Drugs Market in the United Kingdom: Historic Sales Analysis in US$ Million by Disease Type for the Period 2009-2017 |
| United Kingdom Orphan Drugs Market Share Analysis by Disease Type: 2009 VS 2019 VS 2025 |
| Rest of Europe |
| Rest of Europe Orphan Drugs Market Estimates and Forecasts in US$ Million by Drug Type: 2018-2025 |
| Orphan Drugs Market in Rest of Europe in US$ Million by Drug Type: A Historic Review for the Period 2009-2017 |
| Rest of Europe Orphan Drugs Market Share Breakdown by Drug Type: 2009 VS 2019 VS 2025 |
| Rest of Europe Orphan Drugs Market Estimates and Forecasts in US$ Million by Disease Type: 2018-2025 |
| Orphan Drugs Market in Rest of Europe in US$ Million by Disease Type: A Historic Review for the Period 2009-2017 |
| Rest of Europe Orphan Drugs Market Share Breakdown by Disease Type: 2009 VS 2019 VS 2025 |
| Asia-Pacific |
| Orphan Drugs Market in Asia-Pacific by Drug Type: Estimates and Projections in US$ Million for the Period 2018-2025 |
| Asia-Pacific Orphan Drugs Historic Market Scenario in US$ Million by Drug Type: 2009-2017 |
| Asia-Pacific Orphan Drugs Market Share Analysis by Drug Type: 2009 VS 2019 VS 2025 |
| Orphan Drugs Market in Asia-Pacific by Disease Type: Estimates and Projections in US$ Million for the Period 2018-2025 |
| Asia-Pacific Orphan Drugs Historic Market Scenario in US$ Million by Disease Type: 2009-2017 |
| Asia-Pacific Orphan Drugs Market Share Analysis by Disease Type: 2009 VS 2019 VS 2025 |
| Rest of World |
| Rest of World Orphan Drugs Market Estimates and Forecasts in US$ Million by Drug Type: 2018 to 2025 |
| Rest of World Orphan Drugs Historic Market Review by Drug Type in US$ Million: 2009-2017 |
| Orphan Drugs Market in Rest of World: Percentage Share Breakdown of Sales by Drug Type for 2009, 2019, and 2025 |
| Rest of World Orphan Drugs Market Estimates and Forecasts in US$ Million by Disease Type: 2018 to 2025 |
| Rest of World Orphan Drugs Historic Market Review by Disease Type in US$ Million: 2009-2017 |
| Orphan Drugs Market in Rest of World: Percentage Share Breakdown of Sales by Disease Type for 2009, 2019, and 2025 |
| IV. COMPETITION |
| Total Companies Profiled : 151 Click here to request a full table of contents and more details on this project. |
INSIDER ACCESS TO
METHODOLOGY
QUESTIONNAIRE
INFLUENCER NETWORK
Registration is required to access our data stacks.
RESEARCH PANEL
Panelists are carefully chosen based on their domain expertise and market influence.
Participation in our expert panels is only by invitation. Our project focused panels are constituted of senior executives in business strategy, marketing, sales, and product management at competitive companies worldwide. We also welcome individuals from leading management consulting, venture capital, private equity, investment management and related firms with domain expertise and are actively monitoring specific companies or industries. Our panelists bring unique market perspectives and unbiased intelligence to our ongoing research programs.
Our panelists give 30-minutes a month or a one-time 30-minute participation based on their time and willingness.
- Complimentary previews of full stack research data for participated
- Insider access to research programs including engagements and stats from other panelists
- Unlimited research credits of $1000 per participated project
- Competitive Intelligence Alerts including engagements from other panelists and validated participants worldwide relevant to your company
- Interact with other panelists via our MarketGlassTM Data Exchange Platform*
- BlogX - Panelists can use our blogging platform publish their viewpoints on news relevant to their domain expertise. Platform enables panelists to share their viewpoints on current news and events related to their areas domain expertise with timely and insightful blogs*
* Complete details will be shared with panelists upon formal acceptance.
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com